Carlos Medina

Dr. Carlos Medina

Immunology, Stanford University School of Medicine, Stanford, California, USA
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Biomaterials
Verified
Journal Article
Closed access
ESElya A. Shamskhou
Elya A. Shamskhou
MKMichael J. Kratochvil
Michael J. Kratochvil
MOMark E. Orcholski
Mark E. Orcholski
NNNadine Nagy
Nadine Nagy
GKGernot Kaber
Gernot Kaber
VPVinicio A. de Jesus Perez
Vinicio A. de Jesus Perez

1 November 2013 in General and Comparative Endocrinology
Verified
Journal Article
Closed access
CMCarlos Medina
Carlos Medina
CLChristine R. Lattin
Christine R. Lattin
MMM. McVey
M. McVey
LRL. Michael Romero
L. Michael Romero

1 January 2017 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
JGJohn A. Gebe
John A. Gebe
KYKoshika Yadava
Koshika Yadava
SRShannon M. Ruppert
Shannon M. Ruppert
PMPayton Marshall
Payton Marshall
PHPaul Hill
Paul Hill
PBPaul L. Bollyky
Paul L. Bollyky
The extracellular matrix in asthmatic lungs contains abundant low-molecular-weight hyaluronan, and this is known to promote antigen presentation and allergic responses. Conversely, high-molecular-weight hyaluronan (HMW-HA), typical of uninflamed tissues, is known to suppress inflammation. We investigated whether HMW-HA can be adapted to promote tolerance to airway allergens. HMW-HA was thiolated to prevent its catabolism and was tethered to allergens via thiol linkages. This platform, which we call “XHA,” delivers antigenic payloads in the context of antiinflammatory costimulation. Allergen/XHA was administered intranasally to mice that had been sensitized previously to these allergens. XHA prevents allergic airway inflammation in mice sensitized previously to either ovalbumin or cockroach proteins. Allergen/XHA treatment reduced inflammatory cell counts, airway hyperresponsiveness, allergen-specific IgE, and T helper type 2 cell cytokine production in comparison with allergen alone. These effects were allergen specific and IL-10 dependent. They were durable for weeks after the last challenge, providing a substantial advantage over the current desensitization protocols. Mechanistically, XHA promoted CD44-dependent inhibition of nuclear factor-κB signaling, diminished dendritic cell maturation, and reduced the induction of allergen-specific CD4 T-helper responses. XHA and other potential strategies that target CD44 are promising alternatives for the treatment of asthma and allergic sinusitis.

14 July 2014 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
BUBenjamin R. Umiker
Benjamin R. Umiker
GMGabrielle McDonald
Gabrielle McDonald
ALAmma Larbi
Amma Larbi
CMCarlos Medina
Carlos Medina
EHElias Hobeika
Elias Hobeika
TIThereza Imanishi‐Kari
Thereza Imanishi‐Kari
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the presence of pathogenic IgG antinuclear antibodies. Pathogenic IgG autoantibody production requires B‐cell activation, leading to the production of activation‐induced deaminase (AID) and class switching of IgM genes to IgG. To understand how and when B cells are activated to produce these IgG autoantibodies, we studied cells from 564Igi, a mouse model of SLE. 564Igi mice develop a disease profile closely resembling that found in human SLE patients, including the presence of IgG antinucleic acid Abs. We have generated 564Igi mice that conditionally express an activation‐induced cytidine deaminase transgene (Aicdatg), either in all B cells or only in mature B cells. Here, we show that class‐switched pathogenic IgG autoantibodies were produced only in 564Igi mice in which AID was functional in early‐developing B cells, resulting in loss of tolerance. Furthermore, we show that the absence of AID in early‐developing B cells also results in increased production of self‐reactive IgM, indicating that AID, through somatic hypermutation, contributes to tolerance. Our results suggest that the pathophysiology of clinical SLE might also be dependent on AID expression in early‐developing B cells.

1 December 2018 in Current Opinion in Immunology
Verified
Journal Article
Closed access
CMCarlos Medina
Carlos Medina
NNNadine Nagy
Nadine Nagy
PBPaul Bollyky
Paul Bollyky

6 February 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
IKIevgen O. Koliesnik
Ievgen O. Koliesnik
HKHedwich F. Kuipers
Hedwich F. Kuipers
CMCarlos Medina
Carlos Medina
SZSvenja Zihsler
Svenja Zihsler
DLDan Liu
Dan Liu
PBPaul L. Bollyky
Paul L. Bollyky
The heparan sulfate mimetic PG545 (pixatimod) is under evaluation as an inhibitor of angiogenesis and metastasis including in human clinical trials. We have examined the effects of PG545 on lymphocyte phenotypes and function. We report that PG545 treatment suppresses effector T cell activation and polarizes T cells away from Th17 and Th1 and toward Foxp3+ regulatory T cell subsets in vitro and in vivo. Mechanistically, PG545 inhibits Erk1/2 signaling, a pathway known to affect both T cell activation and subset polarization. Interestingly, these effects are also observed in heparanase-deficient T cells, indicating that PG545 has effects that are independent of its role in heparanase inhibition. Consistent with these findings, administration of PG545 in a Th1/Th17-dependent mouse model of a delayed-type hypersensitivity led to reduced footpad inflammation, reduced Th17 memory cells, and an increase in FoxP3+ Treg proliferation. PG545 also promoted Foxp3+ Treg induction by human T cells. Finally, we examined the effects of other heparan sulfate mimetics PI-88 and PG562 on lymphocyte polarization and found that these likewise induced Foxp3+ Treg in vitro but did not reduce Th17 numbers or improve delayed-type hypersensitivity in this model. Together, these data indicate that PG545 is a potent inhibitor of Th1/Th17 effector functions and inducer of FoxP3+ Treg. These findings may inform the adaptation of PG545 for clinical applications including in inflammatory pathologies associated with type IV hypersensitivity responses.